EWTX said the FDA accepted a late-stage design allowing physicians to titrate 7500 by tolerability toward a 150 milligrams target dose. Separate obstructive and non-obstructive HCM trials will use peak VO2 as the primary endpoint and include an adaptive design.
EWTX · Edgewise Therapeutics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 42%
- Last earnings
- May 13, 2024
- Latest filing
- 10-Q · Nov 4
- Price history
- Mar 2021 to Nov 2026
Latest documents
Edgewise Therapeutics, Inc. reported $1,166.2 million in third-quarter net income, including a $1.348 billion gain from the sevasemten sale, and expects to initiate the EDG-7500 Phase 3 trial by year-end 2026.
Edgewise reported that Servier announced on November 3, 2026 that sevasemten’s pivotal GRAND CANYON study in Becker muscular dystrophy missed its primary and secondary endpoints; milestone payments remain contingent on regulatory and commercial outcomes controlled by Servier.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EWTX
this stock
Edgewise Therapeutics, Inc.
|
$4.37B | +60.8% | — | 4.9 | 11.6% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 17
EWTX said the FDA accepted a late-stage design allowing physicians to titrate 7500 by tolerability toward a 150 milligrams target dose. Separate obstructive and non-obstructive HCM trials will use peak VO2 as the primary endpoint and include an adaptive design.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EWTX | -13.1% | +1.5% | +7.1% | +2.6% | +60.8% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -4.6% | +10.7% | +16.3% | +11.3% | +59.7% |